Master Citation Reference
All published pieces — Chicago Manual of Style — compiled June 2026
This document collects every external citation used or recommended across all published One More Beat pieces, organized by article. Each piece carries its own complete citation list. Pieces marked with an asterisk (*) have citations that are candidates for future inline addition — the claims exist in the published text without a source attached, and the appropriate source is identified here.
The Journey
I Chose Life Three Times
No external citations. I Chose Life Three Times is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
Twenty-Two Years…. *
Published without inline citations. The piece contains detailed clinical description of left bundle branch block, ventricular dyssynchrony, biventricular pacemaker implantation, the CRT resynchronization mechanism, and ejection fraction restoration from 25% to 55% following device implantation. The following sources support these claims.
Moss, Arthur J., et al. “Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events.” New England Journal of Medicine 361 (2009): 1329–1338. NEJM.
MADIT-CRT trial. Cited for the reduction in heart failure events from CRT-D in patients with LBBB and reduced ejection fraction. The piece describes the electrophysiologist conditioning the implant on LBBB-specific risk data.
Tang, Anthony S. L., et al. “Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure.” New England Journal of Medicine 363 (2010): 2385–2395. NEJM.
RAFT trial. Cited for the mortality reduction with CRT-D over ICD alone in LBBB patients. Supports the electrophysiologist’s decision to implant a combination biventricular pacemaker-defibrillator.
Ruwald, Martin H., et al. “Long-Term Outcomes of Resynchronization–Defibrillation for Heart Failure.” New England Journal of Medicine 389 (2023). NEJM.
Long-term follow-up of the RAFT trial. Supports the durability of CRT benefit in LBBB patients with reduced ejection fraction over an extended follow-up period.
The Last Decline
No external citations. The Last Decline is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
The Grand Parade *
Published without inline citations. The piece describes the Impella device mechanism and the immediate cognitive restoration following its implantation. The cognitive change is clinically documented in the cerebral blood flow literature below.
Gruhn, N., et al. “Cerebral Blood Flow in Children With Chronic Heart Failure Before and After Heart Transplantation.” Stroke 32, no. 11 (2001): 2537–2544. AHA Journals.
Cited for the documented improvement in cerebral blood flow and cognition following heart transplantation once a working heart restores cardiac output. Supports the description of cognitive restoration as physiological, not attributable to donor influence.
The Bug Zapper
No external citations. The Bug Zapper is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
Out of the Frying Pan *
Published without inline citations. The piece contains detailed pharmacological content on amiodarone-induced thyrotoxicosis, the failure of prednisone and radioactive iodine as treatment options when amiodarone is present in tissue, and the rationale for thyroidectomy as definitive treatment.
Bartalena, Luigi, et al. “Management of Amiodarone-Induced Thyrotoxicosis: A Difficult Clinical Challenge.” Journal of Endocrinological Investigation 41 (2018): 1295–1301. PubMed.
Covers the mechanism of amiodarone-induced thyrotoxicosis, the failure of prednisone and radioactive iodine protocols when amiodarone is present in tissue, and the rationale for thyroidectomy when medical management fails. The piece describes exactly this clinical sequence.
U.S. Food and Drug Administration. “Amiodarone Hydrochloride—Prescribing Information.” FDA.gov.
FDA label. Primary source for the pharmacological claims in the piece: amiodarone’s iodine content (37% by weight), lipophilicity and tissue accumulation, half-life (50–140 days), and active metabolite persistence of 6–12 months after discontinuation.
Standing On Your Own…With Assistance
No external citations. Standing On Your Own…With Assistance is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
Dignity
No external citations. Dignity is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
The Waiting
No external citations. The Waiting is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
November 9th
No external citations. November 9th is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
Post Op / ICU
No external citations. Post Op / ICU is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
The Recovery Ward
No external citations. The Recovery Ward is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
Coming Home
No external citations. Coming Home is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
The Follow-Up Gauntlet *
Published without inline citations. The piece describes the post-transplant surveillance protocol in clinical detail, including the biopsy frequency schedule, the right heart catheterization procedure, and the daily weight-monitoring requirement as a rejection early warning system.
Oh, Jae K., et al. “Protocol Endomyocardial Biopsy Beyond 6 Months—It Is Time to Move On.” American Journal of Transplantation 21, no. 2 (2021): 453–462. American Journal of Transplantation.
Documents the endomyocardial biopsy frequency protocol and the decline in rejection rates with modern immunosuppression. Supports the description of the initial high-frequency schedule and its gradual reduction.
Khush, Kiran K., et al. “The End of Endomyocardial Biopsy?: A Practical Guide for Noninvasive Heart Transplant Rejection Surveillance.” JACC: Heart Failure 11, no. 4 (2023): 389–402. JACC: Heart Failure.
Overview of endomyocardial biopsy as the gold standard for rejection surveillance and the emergence of noninvasive alternatives. Contextualizes the biopsy protocol described in the piece within current ISHLT guideline frameworks.
Sayer, Gabriel, et al. “A Modern Heart Transplant Rejection Surveillance Protocol Utilizing Cell-Free DNA: A Single-Center Experience.” PubMed Central (2025). PubMed Central.
Describes the standard biopsy frequency schedule in the EMBx arm: at 2, 4, 6, and 8 weeks, then at 3, 6, 9, and 12 months for a total of 8 biopsies in year one. Directly supports the frequency described in the piece.
National Institutes of Health. “Heart Transplantation Rejection.” StatPearls. StatPearls / NCBI.
Clinical reference for rejection symptoms including fluid retention and rapid weight gain as early warning signs. Supports daily weight monitoring as a clinically meaningful tool, not administrative protocol.
Life After Transplant
Return *
Published without inline citations. The piece describes cognitive restoration following transplant as the body’s own physiology returning to baseline. The following source documents this mechanism.
Gruhn, N., et al. “Cerebral Blood Flow in Children With Chronic Heart Failure Before and After Heart Transplantation.” Stroke 32, no. 11 (2001): 2537–2544. AHA Journals.
Cited for the documented improvement in cerebral blood flow and cognition following heart transplantation once a working heart restores cardiac output. Supports the description of cognitive restoration as physiological, not attributable to donor influence.
Brain Over Heart *
Published without inline citations. The piece describes cognitive impairment from chronic low cardiac output and the decision to pursue transplant. The following source documents the cerebral blood flow mechanism underlying the cognitive changes described.
Gruhn, N., et al. “Cerebral Blood Flow in Children With Chronic Heart Failure Before and After Heart Transplantation.” Stroke 32, no. 11 (2001): 2537–2544. AHA Journals.
Cited for the documented improvement in cerebral blood flow and cognition following heart transplantation once a working heart restores cardiac output. Supports the description of cognitive restoration as physiological, not attributable to donor influence.
When the Dam Leaks *
Published without inline citations. The piece describes corticosteroid-induced emotional dysregulation in specific clinical detail — the full range of neuropsychiatric effects, the mechanism by which prednisone strips emotional containment, and the dose-dependent nature of the response.
Nanthakumar, Seyon, et al. “Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications.” Diseases 12, no. 12 (2024): 300. PubMed Central.
Comprehensive 2024 review. Covers corticosteroid effects on the HPA axis, dysregulation of stress responses, neurotransmitter alterations (dopamine, serotonin, glutamate), and structural abnormalities in the hippocampus and amygdala linked to mood disorders and anxiety. Mechanism-level support for the piece’s description of prednisone dissolving emotional defenses.
Warris, Lidewij T., et al. “Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis.” Journal of Clinical Endocrinology & Metabolism 109, no. 6 (2024): e1442–e1453. Oxford Academic.
Systematic review and meta-analysis. The most substantial associations with glucocorticoid use were depression and mania. Provides the evidence base for the neuropsychiatric burden described in the piece.
Brown, E. Sherwood, and Alan J. Gelaye. “Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects.” American Journal of Psychiatry 171, no. 10 (2014): 1044–1054. American Journal of Psychiatry.
Cites Boston Collaborative Drug Surveillance Program data: psychiatric disturbances in 18.6% of patients on prednisone above 80mg/day, 4.6% on 41–80mg/day, and 1.3% on under 40mg/day. Supports the dose-dependent framing implicit in the piece.
The Voice *
Published without inline citations. The piece describes left vocal cord paralysis following central venous catheterization, the recurrent laryngeal nerve anatomy, and the working theory of nicking the nerve during swan catheter insertion under difficult conditions.
Fishman, Jonathan M., et al. “Recurrent Laryngeal Nerve Palsy Complicating Subclavian Line Insertion: A Case Report.” Journal of Medical Case Reports 3 (2009): 9034. PubMed Central.
Case report documenting recurrent laryngeal nerve injury via central venous access — the same mechanism identified as the working theory in the piece. References multiple prior case reports of the same complication via the jugular route.
Naidoo, Roshan, and Hazel Margaret Bhagwandeen. “Vocal Cord Paralysis After Open-Heart Surgery.” European Journal of Cardio-Thoracic Surgery 21, no. 4 (2002): 671–674. Oxford Academic.
Reviews eight mechanisms of recurrent laryngeal nerve injury in cardiac surgery, naming central venous catheterization first. Directly supports the anatomical description in the piece of the nerve’s proximity to the insertion path.
Tao, Yinfeng, et al. “Vocal Cord Paralysis and Laryngeal Trauma in Cardiac Surgery.” PubMed Central (2017). PubMed Central.
Reports incidence of 0.67% to 1.9% for vocal cord paralysis in cardiac surgery overall, with 10.7% in the study’s own cohort. Emergency operations were an independent risk factor (OR 97.5). Confirms that hoarseness following cardiac intervention is frequently underestimated.
The Year of Living Carefully
No external citations. The Year of Living Carefully is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
The Fine Print *
Published without inline citations. The piece contains specific clinical claims about tacrolimus side effects — tremor, insomnia, hypomagnesemia, and alopecia — as well as the diabetogenic burden of the combined immunosuppressant regimen and the daily weigh-in as a rejection monitoring tool.
Astellas Pharma US, Inc. “Prograf (Tacrolimus)—U.S. Prescribing Information.” FDA.gov. FDA.gov.
FDA-approved prescribing label. Authoritative source for tacrolimus side effect prevalence: tremors (48–56%), insomnia (32–64%), hypomagnesemia (16–48%), hyperglycemia (70%), alopecia (listed; frequency not reported in label). Directly supports all specific side effect claims in the piece.
Krentz, A. J., et al. “Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients.” Transplantation80, no. 12 (2005): 1546–1549. PubMed.
Documents clinically significant alopecia in 28.9% of tacrolimus-treated recipients versus none in cyclosporine-treated patients (P<0.001). Directly supports the piece’s description of tacrolimus-induced hair loss.
Hauner, Hans. “Diabetogenic Mechanisms of Immunosuppressive Agents.” Transplantation Reviews (2006). PubMed Central.
Covers the mechanisms by which tacrolimus suppresses insulin secretion and sirolimus causes insulin resistance, producing the combined diabetogenic burden described in this piece.
National Institutes of Health. “Heart Transplantation Rejection.” StatPearls. StatPearls / NCBI.
Clinical reference for rejection symptoms including fluid retention and rapid weight gain as early warning signs. Supports daily weight monitoring as a clinically meaningful tool, not administrative protocol.
The Things You Need
Contains product links (Amazon affiliate links for recommended supplies). No external academic or clinical citations.
Health & Management
The Blood Is the Life
Bestard, Oriol, et al. “ITORQ: A Prospective Observational Study to Assess Immune Monitoring in Kidney Transplant Recipients Using the Torque Teno Virus Load as a Marker of the Immunological Status.” American Journal of Transplantation 21, no. 3 (2021): 1076–1085. PubMed Central.
2020 prospective trial cited inline for the target range of balanced immunosuppression as defined by TTV (Torque Teno Virus) load — the clinical anchor for the 10⁶–10⁴ copies/mL range used to calibrate immunosuppression levels.
The Diagnosis Nobody Prepares You For
Kobashigawa, Jon A., et al. “Prevalence and Prognostic Significance of CAV After Heart Transplantation.” Journal of the American College of Cardiology 68, no. 12 (2016): 1221–1231. JACC.
Cited inline for five-year survival data for CAV detected by conventional angiography versus IVUS/OCT, supporting the argument for sensitive imaging.
Imamura, Teruhiko, et al. “Prognostic Impact of Cardiac Allograft Vasculopathy in Heart Transplant Recipients.” Journal of Cardiac Failure 30, no. 3 (2023): 401–408. PubMed.
2023 retrospective study cited inline for the statistic that 20% of recipients showed angiographically significant CAV within the first year of transplant.
Mehra, Mandeep R., et al. “Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years.” JACC: Heart Failure 5, no. 12 (2017): 889–897. JACC: Heart Failure.
30-year outcomes review cited inline for the trajectory of CAV management improvement over the modern transplant era.
Stomberski, Colin T., and Monica M. Colvin. “Cardiac Allograft Vasculopathy: Advances in Diagnosis and Management.” Current Transplantation Reports 12 (2025). PubMed Central.
2025 University of Michigan review; current diagnostic and management landscape for CAV including IVUS/OCT sensitivity and modern treatment options.
The Long Game: Treatment, Management, and What Comes Next
Kobashigawa, Jon A., et al. “Pravastatin After Cardiac Transplantation: Effect on Early Graft Coronary Artery Disease, Acute Rejection, and Allograft Vasculopathy.” New England Journal of Medicine 333, no. 10 (1995): 621–627. PubMed.
Foundational 1995 pravastatin trial cited inline for the anti-inflammatory and immunomodulatory benefit of statins in the transplant population, independent of cholesterol-lowering effects.
Stomberski, Colin T., and Monica M. Colvin. “Cardiac Allograft Vasculopathy: Advances in Diagnosis and Management.” Current Transplantation Reports 12 (2025). PubMed Central.
2025 University of Michigan review; current diagnostic and management landscape for CAV including IVUS/OCT sensitivity and modern treatment options.
Bhatt, Deepak L., et al. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.” New England Journal of Medicine 380 (2019): 11–22. NEJM.
REDUCE-IT trial cited inline for the 25% reduction in major cardiovascular events with icosapent ethyl (Vascepa) at 4g daily. The piece notes this is the same dose used in the trial.
Hauner, Hans. “Diabetogenic Mechanisms of Immunosuppressive Agents.” Transplantation Reviews (2006). PubMed Central.
Covers the mechanisms by which tacrolimus suppresses insulin secretion and sirolimus causes insulin resistance, producing the combined diabetogenic burden described in this piece.
McMurray, John J. V., et al. “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.” The Lancet396 (2020): 1019–1032. The Lancet.
DAPA-HF and EMPEROR-Reduced meta-analysis cited inline for SGLT2 inhibitor cardiovascular benefit, supporting Jardiance use in the piece.
Living with Immunosuppression: What the Science Actually Says
Perez-Aytes, Antonio, et al. “Malignancy After Solid Organ Transplantation in Children: A 10-Year Retrospective Cohort Study.” American Journal of Transplantation 22 (2022). American Journal of Transplantation.
10-year retrospective cohort of 6,271 heart transplants at 32 US centers cited inline for the 4- to 10-fold increase in squamous cell carcinoma incidence post-transplant.
Arron, Sarah T., et al. “Skin Cancer in Organ Transplant Recipients.” PubMed Central (2025). PubMed Central.
Cited inline for the 5:1 SCC-to-BCC ratio reversal in transplant recipients.
Sherston, Sarah N., et al. “Malignancy After Heart Transplantation.” Journal of the American College of Cardiology 70, no. 14 (2017): 1747–1756. JACC.
Cited inline for overall de novo malignancy risk running 2–4-fold above the general population, approximately 20% cumulative incidence at 10 years.
Reshef, Ran, et al. “Post-Transplant Lymphoproliferative Disorders.” Transplantology 3, no. 1 (2022). MDPI.
Cited inline for the median time from transplant to PTLD of approximately 8.5 years.
What to Avoid and Why
Citations are organized by the section of the piece they support.
High-Fat Meals and Tacrolimus Bioavailability
Bekersky, I., D. Dressler, and Q. Mekki. “Effect of Low- and High-Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects.” Journal of Clinical Pharmacology 41, no. 2 (2001): 176–185. PubMed.
Primary study establishing the 37% AUC reduction and fivefold delay in time-to-peak-concentration with a high-fat meal. The basis for the 35–40% bioavailability reduction figure cited in the piece.
Huppertz, A., et al. “Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics.” Clinical Pharmacology in Drug Development 10, no. 5 (2021): 484–494. Wiley.
Covers immediate-release tacrolimus (Prograf) vs. Envarsus XR food effects; confirms 33.4% bioavailability reduction for IR formulation and approximately 55% for Envarsus with high-fat meal. Source for the IR/ER formulation distinction and extended absorption window.
Grapefruit and CYP3A4 Inhibition
Fuhr, U., et al. “Physiologically Based Pharmacokinetic Modeling of Bergamottin and 6,7-Dihydroxybergamottin to Describe CYP3A4-Mediated Grapefruit-Drug Interactions.” Clinical Pharmacology & Therapeutics 114, no. 3 (2023): 670–681. Wiley.
Establishes time-dependent CYP3A4 inhibition lasting more than 24 hours; furanocoumarins act as suicide inhibitors of intestinal CYP3A4; one glass of juice sufficient to cause clinically relevant effect. Source for the 72-hour avoidance guidance.
Nowack, R. “Cytochrome P450 Enzyme, and Transport Protein Mediated Herb–Drug Interactions in Renal Transplant Patients: Grapefruit Juice, St John’s Wort—and Beyond!” Nephrology 13, no. 4 (2008): 337–347. Wiley.
Covers grapefruit, St. John’s Wort, and related interactions specifically in transplant recipients, including cyclosporine, calcium channel blockers, and statins alongside tacrolimus.
Pomegranate
Miedziaszczyk, M., et al. “Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food.” Pharmaceutics 14, no. 10 (2022): 2154. PubMed Central.
Comprehensive review covering tacrolimus interactions with pomegranate, berberine, turmeric, ginger, green tea, valerian, and St. John’s Wort, among others.
Singh, A., et al. “Potential Profound Fluctuation in Tacrolimus Concentration on Consumption of Pomegranate Rind Extract: A Pharmacokinetic Experiment.” Frontiers in Pharmacology 14 (2023): 1140706. PubMed Central.
In vivo and in silico pharmacokinetic study confirming strong CYP isoenzyme interaction between pomegranate rind extract and tacrolimus. Supports the P-glycoprotein inhibition mechanism described in the piece.
Starfruit / Caramboxin Nephrotoxicity
Cossey, L. N., et al. “Oxalate Nephropathy: A Review.” Clinical Kidney Journal 15, no. 2 (2022): 194–204. Oxford Academic.
Comprehensive review of oxalate nephropathy including starfruit/caramboxin toxicity in uraemic patients, vitamin C-induced cases, and secondary oxalosis causing graft loss in transplant recipients.
St. John’s Wort
Nicolussi, S., et al. “Clinical Relevance of St. John’s Wort Drug Interactions Revisited.” British Journal of Pharmacology177, no. 6 (2020): 1212–1226. PubMed Central.
Documents the 2000 heart transplant rejection cases from SJW/cyclosporine interaction; covers tacrolimus, warfarin, and other substrates; explains PXR activation and CYP3A4/P-glycoprotein induction mechanism.
“St. John’s Wort Interactions: What’s New?” Pharmacy Times, May 2004. Pharmacy Times.
Clinical summary documenting organ rejection cases from SJW use. Notes that depression is common post-transplant, making SJW a particularly high-risk supplement in this population.
CBD / Cannabidiol
Leino, A. D., et al. “Evidence of a Clinically Significant Drug–Drug Interaction between Cannabidiol and Tacrolimus.” American Journal of Transplantation 19, no. 10 (2019): 2944–2948. PubMed.
Primary clinical case report: approximately threefold increase in dose-normalized tacrolimus concentrations with CBD co-administration. University of Cincinnati research. The foundational published case for the interaction described in the piece.
So, S., et al. “Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro.” Clinical and Translational Science 18 (2025): e70152. PubMed Central.
Most recent mechanistic study clarifying CYP3A4 and CYP3A5 inhibition by CBD and its metabolites.
Cannabis Inhalation and Aspergillus
Ruchlemer, R., et al. “Inhaled Medicinal Cannabis and the Immunocompromised Patient.” Supportive Care in Cancer23, no. 3 (2015): 819–822. Lumir Lab.
Covers Aspergillus exposure risk via inhaled cannabis in immunocompromised patients including solid organ transplant recipients. Notes that marijuana smoke may damage alveolar macrophage function. References invasive aspergillosis cases in renal transplant recipients associated with cannabis smoking.
NSAIDs and Calcineurin Inhibitors
Golightly, L. K., et al. “Calcineurin Inhibitor and Nonsteroidal Anti-inflammatory Drug Interaction: Implications of Changes in Renal Function Associated With Concurrent Use.” Journal of Clinical Pharmacology 58, no. 10 (2018): 1342–1351. PubMed.
Documents 80.5% rate of creatinine increase in CNI patients exposed to concurrent NSAIDs versus 56.3% in unexposed; NSAID administration was an independent predictor of rapid creatinine rise. Concludes concurrent use inadvisable.
Schlondorff, D. “Nonsteroidal Anti-Inflammatory Drugs and the Kidney.” Pharmaceuticals 3, no. 7 (2010): 2291–2321. MDPI.
Covers the renal vasoconstriction mechanism; explicitly recommends acetaminophen in place of NSAIDs for transplant recipients on cyclosporine or tacrolimus. Supports the piece’s recommendation.
Vitamin C and Oxalate Nephropathy
Shen, Z. Y., et al. “High-Dose Vitamin C-Induced Acute Oxalate Nephropathy in a Renal Transplant Recipient: A Case Report and Literature Review.” Asian Journal of Surgery 46, no. 5 (2023): 2223–2224. PubMed.
Directly applicable: renal transplant recipient; documents the vitamin C-to-oxalate-to-nephropathy pathway. Supports the piece’s description of oxalate nephropathy as one of two reasons for the 1-gram daily ceiling.
Cossey, L. N., et al. “Oxalate Nephropathy: A Review.” Clinical Kidney Journal 15, no. 2 (2022): 194–204. Oxford Academic.
Comprehensive review of oxalate nephropathy including starfruit/caramboxin toxicity in uraemic patients, vitamin C-induced cases, and secondary oxalosis causing graft loss in transplant recipients.
Regulatory Gap — DSHEA and German Commission E
U.S. Food and Drug Administration. “Dietary Supplements.” FDA.gov. FDA.gov.
Primary government source for the DSHEA regulatory framework and the FDA’s post-market oversight role. Source for the piece’s description of what manufacturers are not required to prove before selling a supplement.
American Botanical Council. “Commission E Monographs.” HerbalGram. HerbalGram.
Best accessible English-language source for explaining the German Commission E evaluation process and the monograph format. Source for the Apotheke/regulatory contrast in the piece.
“Transplant Immunosuppressants: Common Drug Interactions.” Pharmacy Times, February 2006. Pharmacy Times.
Clinically oriented overview covering grapefruit, St. John’s Wort, and herbal supplements in the transplant context. Accessible framing for general clinical citation.
The Magnesium Problem
Magnesium Physiology — General
de Baaij, Jeroen H.F., Joost G.J. Hoenderop, and René J.M. Bindels. “Magnesium in Man: Implications for Health and Disease.” Physiological Reviews 95, no. 1 (2015): 1–46. https://journals.physiology.org/doi/full/10.1152/physrev.00012.2014.
Primary comprehensive reference for magnesium physiology. Source for the 300/600 enzymatic reactions figure (noting 300 was a 1980 estimate and over 600 is the current enzymatic database count), the 1% serum distribution figure, and the 50–60% bone storage figure. The authoritative single-source citation for the What Magnesium Actually Does and A Note on Serum Levels sections.
Tacrolimus-Induced Hypomagnesemia — Mechanism and Incidence
Navaneethan, S.D., S. Sankarasubbaiyan, M.D. Gross, V. Jeevanantham, and R.D. Monk. “Tacrolimus-Associated Hypomagnesemia in Renal Transplant Recipients.” Transplantation Proceedings 38, no. 5 (2006): 1320–1322. https://pubmed.ncbi.nlm.nih.gov/16797291/.
Primary clinical study. 41 renal transplant patients on tacrolimus plus 10 healthy controls. Key findings: 43% of tacrolimus-treated patients displayed hypomagnesemia; fractional excretion of magnesium 7.42% vs. 1.88% in controls (nearly fourfold higher); 24-hour urinary magnesium excretion 112.36 mg/dL vs. 6.7 mg/dL in controls. Tacrolimus trough level was the single best predictor of urinary magnesium loss. Magnesium replacement did not influence fractional excretion or 24-hour urinary excretion, confirming the permanent nature of the wasting mechanism. Source for the 43% incidence and the fractional excretion data cited in the piece.
Chaves, M., et al. “Prevalence, Risk Factors and Potential Protective Strategies for Hypomagnesemia in Kidney Transplant Recipients.” International Journal of Molecular Sciences 26, no. 13 (2025): 6528. https://doi.org/10.3390/ijms26136528.
2025 review and cohort study. Documents TRPM6 downregulation by tacrolimus as the primary renal wasting mechanism; confirms dose-dependent effect (patients with hypomagnesemia had significantly higher tacrolimus trough levels: 8.22 vs. 7.68 ng/mL, p=0.03). Also covers sirolimus/mTOR inhibitor effects and the protective role of SGLT2 inhibitors on magnesium homeostasis. Source for the TRPM6 mechanism section.
Proton Pump Inhibitors and Hypomagnesemia in Transplant Recipients
Florentin, M., et al. “Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients.” Journal of Clinical Medicine 8, no. 12 (2019): 2162. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947083/.
686 stable outpatient kidney transplant recipients, functioning allograft ≥1 year. 56.6% on PPIs. Key findings: PPI use associated with lower plasma magnesium (β: −0.02, P=0.02) and lower 24-hour urinary excretion (β: −0.82, P<0.001). PPI users had more than twice the odds of hypomagnesemia vs. non-users (OR: 2.12; 95% CI 1.43–3.15, P<0.001). Risk was highest at high PPI doses (>20mg omeprazole Eq/day) and was independent of tacrolimus use. Source for the two-front war framing and the OR 2.12 figure in the piece.
Magnesium Supplement Bioavailability — Forms Comparison
Firoz, M., and M. Graber. “Bioavailability of US Commercial Magnesium Preparations.” Magnesium Research 14, no. 4 (2001): 257–262. https://pubmed.ncbi.nlm.nih.gov/11794633/.
Comparative bioavailability study of four commercially available magnesium preparations. Fractional absorption of magnesium oxide was approximately 4%, significantly lower than organic forms. Source for the 4% absorption rate figure cited in the piece and the basis for the magnesium oxide section. Often cited alongside the Shils 1999 data on inorganic vs. organic magnesium salt absorption.
Pelletier-Vicuna, C.M., et al. “Bioavailability of Magnesium Food Supplements: A Systematic Review.” Clinical Nutrition40, no. 6 (2021): 3605–3614. https://www.sciencedirect.com/science/article/abs/pii/S0899900721001568.
Systematic review of magnesium supplement bioavailability. Covers the two absorption mechanisms (active TRPM6-mediated transport at lower doses; passive paracellular diffusion at higher doses), the dipeptide transporter (PEPT1) pathway for amino acid chelates including magnesium glycinate, and the dose-dependent nature of the saturation ceiling. Source for the absorption mechanism section and the glycinate PEPT1 pathway description.
Mycophenolate Interaction with Magnesium-Containing Antacids
Novartis Pharmaceuticals. “Myfortic (Mycophenolate Sodium)—U.S. Prescribing Information.” FDA.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021850s031lbl.pdf.
FDA-approved prescribing label. Documents the pharmacokinetic interaction between magnesium-aluminum-containing antacids and mycophenolate sodium (Myfortic): concurrent administration in 12 stable renal transplant patients reduced mean Cmax by 25% and AUC by 37%. Recommends administration separation. Source for the 25%/37% reduction figures cited in the interactions section. The same interaction is documented in the CellCept (mycophenolate mofetil) prescribing information with similar magnitude.
Outstanding Verification Note
• ThyroMag trial (2025), cited in the levothyroxine interaction paragraph — the first study to examine magnesium-levothyroxine interaction specifically, prior guidance having been extrapolated from calcium and iron data. A verified PubMed citation was not located during the research pass for this piece. Confirm the trial name, journal, and authors before the piece goes to press or the interaction paragraph is updated to remove the specific trial reference.
All About Tacrolimus
FDA Prescribing Information
Astellas Pharma US, Inc. “PROGRAF (tacrolimus) Prescribing Information.” DailyMed, National Library of Medicine. Last revised August 2023. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f667de1-9dfa-4bd6-8ba0-15ee2d78873b.
Primary source for all adverse reaction frequencies cited in the piece: tremor (48–56%), insomnia (32–64%), hypomagnesemia (16–48%), and hyperglycemia (listed among the most common adverse reactions at ≥15%). Also the source for the dosing table, therapeutic drug monitoring guidance, CYP3A4 drug interaction warnings, and the contraindication for concomitant use with sirolimus in heart transplant. Cited three times in the article: in the opening FDA approval reference, the “Too High” section, and the Side Effects introduction.
Fat Content and Tacrolimus Absorption
Bekersky, Ivan, Robert M. Fielding, David E. Dressler, John W. Lee, David N. Buell, and Leslie Z. Benet. “Effect of Low‐ and High‐Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects.” Journal of Clinical Pharmacology 41, no. 2 (2001): 176–182. https://pubmed.ncbi.nlm.nih.gov/11210398/.
Three-period crossover study in 15 healthy male volunteers. Established that high-fat meals reduce tacrolimus AUC by approximately 35–40% and delay Tmax from 1.37 hours (fasted) to 6.47 hours (high-fat). Low-fat meals produced intermediate reduction. Primary citation for the fat-content absorption section and the consistency-over-perfection principle in dosing.
Grapefruit and CYP3A4 Inhibition
Bailey, David G., George Dresser, and J. Malcolm O. Arnold. “Grapefruit–Medication Interactions: Forbidden Fruit or Avoidable Consequences?” Clinical Pharmacology & Therapeutics (2013). https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2968.
Cited for the mechanism and duration of grapefruit’s CYP3A4 inhibition via furanocoumarins, and specifically the finding that a single glass of grapefruit juice can impair tacrolimus metabolism for up to 72 hours. Supports the absolute contraindication on grapefruit in the drug interaction section.
Tacrolimus-Induced Alopecia
Tricot, Leila, Céleste Lebbé, Evangéline Pillebout, Frank Martinez, Christophe Legendre, and Eric Thervet. “Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients.” Transplantation 80, no. 11 (December 15, 2005): 1546–1549. https://pubmed.ncbi.nlm.nih.gov/16371923/.
Retrospective cohort study of 58 simultaneous kidney-pancreas transplant recipients. Clinically significant alopecia in 28.9% of tacrolimus-treated patients versus 0% in cyclosporine-treated patients (P<0.001). Cited for the ~29% incidence figure and the comparative finding against cyclosporine. Noted female predominance (11 of 13 alopecia cases were female). Source for the hair loss paragraph in the Side Effects section.
ISHLT Registry Data — Long-Term Outcomes and Renal Dysfunction
International Society for Heart and Lung Transplantation. “ISHLT Transplant Registry.” ISHLT Registries. https://ishltregistries.org/registries/slides.asp.
Cited for the registry-level finding that chronic renal dysfunction is among the leading long-term complications after heart transplantation, and that tacrolimus is the primary pharmacologic driver. Supports the nephrotoxicity discussion in the Side Effects section and the Narrow Road closing argument. Registry data are updated annually; readers should consult the current slides for the most recent figures.
Reflections
Gratitude and Its Complications
No external citations. Gratitude and Its Complications is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
And Yet
No external citations. And Yet is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
Am I Still Me?
Carroll, Robert Todd. “Cellular Memory.” The Skeptic’s Dictionary. Skeptic’s Dictionary.
Cited inline as the authoritative skeptical assessment of the cellular memory hypothesis as “magical thinking dressed in the vocabulary of physics.”
Bhavsar, Sohail, et al. “Personality Changes Following Heart Transplantation.” Transplantology 5, no. 1 (2024). MDPI.
2024 cross-sectional study cited inline: 89% of organ recipients reported personality changes post-surgery, but heart recipients were no more likely to report changes than kidney, liver, or lung recipients. Cited to rebut donor personality transfer claims on evidential grounds.
Gruhn, N., et al. “Cerebral Blood Flow in Children With Chronic Heart Failure Before and After Heart Transplantation.” Stroke 32, no. 11 (2001): 2537–2544. AHA Journals.
Cited for the documented improvement in cerebral blood flow and cognition following heart transplantation once a working heart restores cardiac output. Supports the description of cognitive restoration as physiological, not attributable to donor influence.
Not Yet
No external citations. Not Yet is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.
Outstanding Verification Notes
The following claims appear in published pieces and require citation verification or formal addition before any final citations page is published:
• Magnesium 30% absorption reduction with tacrolimus (What to Avoid and Why) — cited in clinical transplant pharmacy practice but not yet tied to a specific peer-reviewed pharmacokinetic study. The Prograf FDA prescribing information documents the magnesium-aluminum hydroxide antacid interaction without stating the 30% figure. Verify before publication.
• Marks et al. 1996 Aspergillus/transplant case (What to Avoid and Why) — referenced in secondary sources as: Marks WH, et al. Transplantation 61(12):1771–1774, 1996. Obtain direct PubMed PMID to confirm.
• Ashwagandha T-cell immune stimulation (What to Avoid and Why) — well-documented in the adaptogens literature. A transplant-specific citation is needed for this piece’s audience.
• Pearsall, Paul. The Heart’s Code (Am I Still Me?) — referenced in the piece but not formally cited. Full citation: Pearsall, Paul. The Heart’s Code. New York: Broadway Books, 1998.
• Schwartz and Russek paper (Am I Still Me?) — confirm which paper is intended before formal citation.
• Tacrolimus alopecia in The Fine Print — Krentz et al. 2005 provides the strongest peer-reviewed incidence figure. The Prograf FDA label lists alopecia as “frequency not reported.” Both citations together provide comprehensive coverage.